Evidence map›Paper›PMID 11161372›Full record

Trial reportBritish journal of cancer2001

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.

P A Vasey, R Atkinson, R Coleman, M Crawford, M Cruickshank, P Eggleton, D Fleming, J Graham, D Parkin, J Paul and 2 more

Registry-linked trialOpen access · hybridAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00484666 (A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00484666 withdrawnnot on this mapstarted 2006, after this paper: background citation

A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

TypeobservationalSponsorCarilion ClinicRan2006 to 2009Enrolled0ConditionsOvarian Cancer
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 80 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Therapeutic strategies in epithelial ovarian cancer.Journal of experimental & clinical cancer research : CR · 2012
    Review
  11. Article
  12. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2005
    Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

P A VaseyCRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT.
R Atkinson
R Coleman
M Crawford
M Cruickshank
P Eggleton
D Fleming
J Graham
D Parkin
J Paul
N S Reed
S B Kaye
Beatson West of Scotland Cancer Centre · GBAberdeen Royal Infirmary · GBWestern Infirmary · GBAiredale General Hospital · GBAt Bristol · GBUniversity of Ulster · GBWeston Park Cancer Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic-IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28-85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m(2)); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to toxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4%) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II-III neurotoxicity (all sensory; no motor > grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66% (49/74); CA125 response was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3-19.1). Recommended doses are carboplatin AUC 5 (via(51)Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m(2). A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment.

Indexed as

TaxoidsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinConstipationDiarrheaDocetaxelDose-Response Relationship, DrugFatigueFemaleHematologic DiseasesHumansMiddle AgedCarboplatinDocetaxelPaclitaxelTaxoids

Identifiers

PMID11161372
PMCPMC2363708
OpenAlexW1981146671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.